1. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P (1996) Autoantibodies against erytropoietin in a patient with pure red cell aplasia. N Engl J Med 334:630–633
2. Curren RD, Southee JA, Spiedelman H, Liebsch M, Fentem JH, Balls M (1995) The role of prevalidation and validation in the development, validation and acceptance of alternative methods (the first report of ECVAM task force and prevalidation). ATLA 23:409–470
3. Deldar A, Parchment RE (1997) Preclinical risk assessment for hematoxicity: animal models and in vitro systems. In: Sipes G, McQueen CA, Gandolfi AJ (eds) Comprehensive toxicology. Pergamon Press, New York, pp 303–320
4. Deldar A, Stevens CE (1993) Development and application of in vitro models of hematopoiesis to drug development. Toxicol Pathol 21:231–240
5. Dessypris EN (1991) The biology of pure red cell aplasia. Semin Hematol 28:275–284